| Completed | Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in A NCT04368559 | Mundipharma Research Limited | Phase 3 |
| Completed | Study With BioCool Footcare in Subjects With Tinea Pedis Interdigitalis and Heel Cracks, Calluses and/or Dry F NCT04265521 | Biocool AB | N/A |
| Completed | Anti-fungal Strategies in Acute-on-Chronic Liver Failure Patients NCT04157465 | Post Graduate Institute of Medical Education and Research, Chandigarh | N/A |
| Terminated | A Study of Itraconazole in the Management of Superficial Fungal Infections in India NCT03923010 | Janssen Research & Development, LLC | Phase 4 |
| Completed | Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis NCT03667690 | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 |
| Completed | Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization NCT02888197 | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | — |
| Completed | CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidias NCT02734862 | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Completed | RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections NCT02733432 | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Completed | Descriptive Epidemiology on Management of Mucormycosis NCT03429023 | Fungal Infection Study Forum | — |
| Completed | Invasive Mould Infections in Indian ICUs - Descriptive Epidemiology, Management and Outcome NCT02683642 | Fungal Infection Study Forum | — |
| Unknown | Validation of Pathologic Diagnosis of Invasive Fungal Infection by Molecular Method NCT02676570 | Seoul St. Mary's Hospital | — |
| Completed | Effect of Inflammation on Pharmacokinetics of Posaconazole NCT02492802 | University Medical Center Groningen | — |
| Completed | Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candid NCT02244606 | Scynexis, Inc. | Phase 2 |
| Recruiting | Prospective Data Bank Creation to Study Vaginal Conditions NCT01829204 | Texas Tech University Health Sciences Center | — |
| Completed | Assessment of the Fungal Infection Incidence Across Canada for High Risk Participants With Hematological Disea NCT01254318 | Merck Sharp & Dohme LLC | — |
| Completed | Bioequivalence Study for Terbinafine 250 mg NCT01772212 | GlaxoSmithKline | Phase 1 |
| Completed | Effect of Weight and/or Obesity on Anidulafungin Drug Concentrations NCT01307930 | Texas Tech University Health Sciences Center | Phase 4 |
| Completed | A Study to Evaluate Pre-emptive Treatment for Invasive Candidiasis in High Risk Surgical Subjects NCT01122368 | Astellas Pharma Inc | Phase 2 |
| Completed | Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients NCT00841971 | University of Pittsburgh | Phase 4 |
| Unknown | Pre-hospital Risk Factors for Invasive Fungal Infection NCT01315925 | Catholic University of the Sacred Heart | — |
| Completed | Liver Transplant European Study Into the Prevention of Fungal Infection NCT01058174 | Astellas Pharma Inc | Phase 3 |
| Completed | Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Al NCT01232504 | Xiamen Amoytop Biotech Co., Ltd. | Phase 4 |
| Completed | Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma NCT00896493 | Stanford University | Phase 2 |
| Unknown | Caspofungin as Prophylaxis in High Risk Liver Transplantation Recipients NCT01260974 | Azienda Ospedaliera di Padova | Phase 2 |
| Completed | Therapeutic Drug Monitoring of Voriconazole NCT00890708 | Seoul National University Hospital | N/A |
| Withdrawn | Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections in Immuncompromised Patients in Austria NCT00704951 | Merck Sharp & Dohme LLC | — |
| Unknown | Therapeutic Drug Monitoring (TDM) of Voriconazole and Correlation With CYP2C19 Genotype in Korean Populations NCT00673348 | The Catholic University of Korea | — |
| Completed | A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and NCT00784368 | Janssen Pharmaceutical K.K. | Phase 3 |
| Completed | A Study to Examine the Efficacy and Safety of Posaconazole When Introduced Early in the Treatment of Refractor NCT00550732 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections NCT00413218 | Astellas Pharma Inc | Phase 3 |
| Completed | Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transpl NCT00336531 | Samsung Medical Center | Phase 4 |
| Completed | Post-marketing Surveillance Study of Invasive Mycosis With Posaconazole (Study P04641) NCT00726609 | Merck Sharp & Dohme LLC | — |
| Completed | Voriconazole as Prophylaxis for Liver Transplant Recipients NCT00177788 | University of Pittsburgh | — |
| Completed | Emergency Use of Voriconazole in Patients With Life-Threatening Invasive Fungal Infections NCT00015665 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095) NCT00034632 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Tre NCT00034671 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Voriconazole to Prevent Systemic Fungal Infections in Children NCT00005912 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Voriconazole to Treat Fungal Infections NCT00001940 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone NCT00001937 | National Cancer Institute (NCI) | Phase 3 |
| Completed | New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia NCT00342589 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voricon NCT00001810 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients With Graft vs. Host Disease NCT00034645 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P00041) NCT00034658 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever NCT00001790 | National Cancer Institute (NCI) | Phase 1 |
| Completed | An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voricon NCT00001757 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | Itraconazole for the Prevention of Fungal Infections in Chronic Granulomatous Disease NCT00001280 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Approved For Marketing | Single Patient Treatment of Posaconazole in Invasive Fungal Infections (Study P05113) NCT00686621 | Merck Sharp & Dohme LLC | — |
| Completed | A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections NCT00002277 | Pfizer | Phase 3 |
| Completed | Non-Comparative Study of Fluconazole in Patients With Serious Mycoses and Who Cannot Be Treated With Conventio NCT00002038 | Pfizer | N/A |
| Completed | Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal In NCT00000676 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole-Trimethoprim NCT00000826 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where F NCT00002325 | Pfizer | N/A |
| Completed | A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobact NCT00002122 | Pfizer | Phase 3 |